AMGN Stock DD Amgen Inc. 10/04/2014 23:23:25

New Post Public Reply Private Reply Replies (0) Message Board

Oct 5, 2014 at 12:23 AM

AMGN Amgen Inc. $AMGN Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=AMGN&...mp;yt0=Go!

Last Updated: 10/04/2014 23:23:21

Current Price and Quotes
Last Price 139.15
Previous Close 137.20 Open 138.07
Daily Range 137.90 - 139.71 52wk Range 105.76 - 144.46
Volume 3,429,021 Dividend 2.44
Average Vol (30d) 3,009,047 Yield 1.7535

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 18,676,000 17,265,000 15,582,000 15,053,000
Cost of Revenue 3,346,000 3,199,000 2,708,000 2,220,000
Gross Profit 15,330,000 14,066,000 12,874,000 12,833,000
Operating Expenses

Research and Development 4,083,000 3,380,000 3,167,000 2,894,000
Sales, General and Admin. 5,380,000 5,109,000 5,395,000 4,100,000
Non-Recurring Items - - - -
Other - - - 294,000
Operating Income 5,867,000 5,577,000 4,312,000 5,545,000
Income From Continuing Operations

Add'l Income/Expense Items 420,000 485,000 448,000 376,000
Earnings Before Interest and Tax 6,287,000 6,062,000 4,760,000 5,921,000
Interest Expense 1,022,000 1,053,000 610,000 604,000
Earnings Before Tax 5,265,000 5,009,000 4,150,000 5,317,000
Income Tax 184,000 664,000 467,000 690,000
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 5,081,000 4,345,000 3,683,000 4,627,000
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 5,081,000 4,345,000 3,683,000 4,627,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 5,081,000 4,345,000 3,683,000 4,627,000

Recent News

Oct 1, 2014 Global Biosimilar Market Outlook 2018
Oct 1, 2014 The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol
Oct 1, 2014 Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy Of Dermatology And Venereology
Oct 1, 2014 Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter
Oct 1, 2014 TeselaGen Receives $750k NSF SBIR Phase II Award
Sep 30, 2014 Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents
Sep 25, 2014 Research and Markets: Acute Coronary Syndrome - Current and Future Players: Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GSK, Janssen Pharma, Merck, Pfizer & Sanofi
Sep 24, 2014 Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress
Sep 24, 2014 Galectin Therapeutics Elects Gilbert S. Omenn, M.D., Ph.D., a Leading Cancer Researcher, to Its Board of Directors
Sep 24, 2014 ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise

1
2
3
4
5
6
7
8
next >